5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Relapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received 5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with 5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted.

Original languageEnglish (US)
Pages (from-to)754-758
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Issue number5
StatePublished - May 2011
Externally publishedYes


  • 5-Azacytidine
  • Acute myeloid leukemia
  • Donor lymphocyte infusion
  • Graft-versus-host disease
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of '5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation'. Together they form a unique fingerprint.

Cite this